FDA Approves Cadila’s Generic Parkinson’s Drug- Latest News
Zydus Pharmaceuticals (USA) Inc, Cadila Healthcare’s subsidiary, has now received the FDA nod for its Pramipexole Dihydrochloride extended-release tablets, used for treating Parkinson’s disease, in the American market.
Pramipexole Dihydrochloride extended-release tablets in strengths of 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg, are now approved by the FDA Cadila Healthcare said in a statement.
The group also received the final approval from the USFDA to market Nitrofurantoin Capsules USP (macrocrystals), 50 mg and 100 mg, which is indicated to treat acute uncomplicated urinary tract infections. Both the drugs will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
